Calls for papers

In this cross-journal Collection, we welcome submissions of articles that focus on the basic principles, method developments, and applications of RNA-based therapeutics.

In this cross-journal Collection, we invite submissions of primary research articles that focus on preclinical and clinical development of immune cell-based therapies for cancer treatment.

This cross-journal Collection between Nature Communications, Communications Biology, npj Genomic Medicine and Scientific Reports brings together research articles that provide new insights into the biology of rare genetic disorders, also known as Mendelian or monogenic disorders.

This joint collection welcomes clinical, epidemiological, and public health research focused on multimorbidity.

This cross-journal Collection welcomes submissions of original preclinical and clinical research studies focused on addressing unmet needs in organ transplantation.

This Collection will highlight Articles that involve new tools and emerging techniques for imaging at increased penetration depths within tissue as well as considering advances in conventional and state-of-the-art light microscopy techniques.

This joint collection welcomes submissions that advance our understanding of the mental and physical impact of working in healthcare on the health of healthcare workers.

In this collection, we want to highlight research that focuses on fragments in drug discovery. Have you found validated fragment hits for a new disease target? Maybe they unlocked an unreported enzyme mechanism? Were you able to develop a method that is useful for fragment-based drug discovery? Perhaps you found a hit that made it to clinical trials? We invite all scientists who work with fragments in the context of drug discovery to submit their interesting fragment stories. We look forward to hearing all about them.

With this collection, Nature Communications, Nature Medicine, Communications Medicine and Scientific Reports aim to publish research articles spanning the breadth of AMR and across microbial pathogens (bacteria, viruses, fungi and parasites). This includes, and is not limited to epidemiological monitoring of resistance incidence in clinical and environmental settings, novel strategies aiming to combat or prevent AMR (i.e. drug repurposing, drug synergy treatment, and vaccines), improvements in diagnostics, and subsequently tailored treatment, of drug-resistant infections.

This collection aims to improve understanding how the immune system changes during aging and welcomes submissions to Nature Communications, Communications Biology, and Scientific Reports.